Faculty of Hepato-Pancreato-Biliary Surgery, the First Medical Centre, Chinese PLA General Hospital, Beijing, China.
Senior Departments of Urology, the Third Medical Centre, Chinese PLA General Hospital, Beijing, China.
Front Immunol. 2024 Jan 4;14:1272108. doi: 10.3389/fimmu.2023.1272108. eCollection 2023.
Tubulin epsilon and delta complex 2 (TEDC2) is widely expressed in various human tissues and primarily governs centriole stability. However, the biological significance of TEDC2 in pan-cancer is unclear.
In this study, we employed R software and various online bioinformatics analysis tools to investigate the functional attributes of TEDC2 in human tumours and its potential involvement in immune response. The status of TEDC2 expression was evaluated in samples from the TCGA and GEO datasets, as well as in tumour and corresponding normal samples from the TCGA database. Subsequently, Kaplan-Meier estimates, clinical correlations, and univariate Cox regressions were used to analyze the 33 types of tumors from TCGA and determine the prognostic significance of TEDC2. Moreover, nomogram models were formulated using three distinct tumours, namely kidney renal clear cell carcinoma (KIRC), lung adenocarcinoma (LUAD), and liver hepatocellular carcinoma (LIHC), to evaluate the prognostic significance of TEDC2 in tumours. Furthermore, TEDC2 was investigated for its correlation with the levels of immune cell infiltration, and a functional enrichment analysis was conducted to identify potential signalling pathways involving TEDC2.
Differential analysis revealed that 16 tumour types expressed TEDC2 to a greater extent than normal tissues. The abnormal expression of TEDC2 can predict survival outcomes in patients with adrenocortical carcinoma (ACC), KIRC, kidney renal papillary cell carcinoma (KIRP), LUAD, LIHC, lower grade glioma (LGG), and thymoma (THYM). Subsequent results indicated that TEDC2 has the ability to influence ECM regulators, cell cycle, and Immune checkpoint-associated signalling pathways, which could potentially lead to a poor prognosis and tumour progression.
TEDC2 has been identified as a potential therapeutic target that could predict the prognosis of multiple tumour types, making it a promising target for reversing tumour development.
微管蛋白 ε 和 δ 复合物 2（TEDC2）广泛表达于各种人体组织中，主要调控中心体的稳定性。然而，TEDC2 在泛癌症中的生物学意义尚不清楚。
本研究采用 R 软件和各种在线生物信息学分析工具，研究了 TEDC2 在人类肿瘤中的功能特征及其潜在的免疫反应参与情况。我们评估了 TCGA 和 GEO 数据集样本中 TEDC2 的表达状态，以及 TCGA 数据库中肿瘤和相应正常样本中的 TEDC2 表达状态。随后，我们采用 Kaplan-Meier 估计、临床相关性和单变量 Cox 回归分析了来自 TCGA 的 33 种肿瘤类型，并确定了 TEDC2 的预后意义。此外，我们使用三种不同的肿瘤（即肾透明细胞癌（KIRC）、肺腺癌（LUAD）和肝细胞癌（LIHC））构建了列线图模型，以评估 TEDC2 在肿瘤中的预后意义。此外，我们研究了 TEDC2 与免疫细胞浸润水平的相关性，并进行了功能富集分析，以确定涉及 TEDC2 的潜在信号通路。
差异分析表明，16 种肿瘤类型的 TEDC2 表达水平高于正常组织。TEDC2 的异常表达可以预测肾上腺皮质癌（ACC）、KIRC、肾乳头细胞癌（KIRP）、LUAD、LIHC、低级别胶质瘤（LGG）和胸腺瘤（THYM）患者的生存结局。随后的结果表明，TEDC2 能够影响 ECM 调节剂、细胞周期和免疫检查点相关信号通路，这可能导致不良预后和肿瘤进展。
TEDC2 已被确定为一种潜在的治疗靶点，可预测多种肿瘤类型的预后，因此可能成为逆转肿瘤发展的有前途的靶点。
